Stock Exchange News - MYRX - MYRX Shares Completion of Spin Off of Its Study and Pharmaceutical Business - Sourced WhisperFromWallStreet.com
COMPANY - Myriad Pharmaceuticals, Inc.,MYRX
NEWS - Myriad Genetics, Inc.announced today the successful completion of the spin off of Myriad Pharmaceuticals, Inc., and that Myriad Genetics has received a Private Letter Ruling from the Internal Revenue Service that the dividend of common stock of Myriad Pharmaceuticals to Myriad Genetics shareholders qualifies as a tax free distribution for U.S. income tax purposes.On June 30, 2009, shareholders of record of Myriad Genetics as of June 17, 2009, received a pro-rata dividend of 1/4 share of Myriad Pharmaceuticals common stock for each share of Myriad Genetics common stock. Fractional shares were paid in cash.
Last Trade: 4.28
Day's Range: N/A - N/A
52wk Range: 3.63 - 7.49
Volume: 0
ABOUT - Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of therapeutic drug candidates. The company?s activities include identification of drug targets, discovery of molecules, development of drug candidates, and design and execution of clinical programs. It develops four drug candidates that involve in human clinical trials, as well as engages in the research and development of cancer and infectious disease drugs. The company was founded in 1998 and is based in
---
WhisperFromWallStreet is a news letter focusing on sending specific alerts to our subscribers. These alerts represent which stocks we believe are going to run. Additionally we spend time teaching how to become a better trader. If you like more information or to Sign Up for free alerts, visit us at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT INFORMATION: Nothing in this press release should be interpreted as a solicitation to buy any stock or security represented herein. WhisperfromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers. Information presented here is based on our opinion only.
